Triple-negative breast cancer (TNBC) accounts for approximately 10–20% of all breast cancers and is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Here, ERBB2 is linked to triple-negative breast carcinoma.